JP2024519814A - 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物 - Google Patents

指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物 Download PDF

Info

Publication number
JP2024519814A
JP2024519814A JP2023571295A JP2023571295A JP2024519814A JP 2024519814 A JP2024519814 A JP 2024519814A JP 2023571295 A JP2023571295 A JP 2023571295A JP 2023571295 A JP2023571295 A JP 2023571295A JP 2024519814 A JP2024519814 A JP 2024519814A
Authority
JP
Japan
Prior art keywords
moiety
compound
independently
interest
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571295A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022245759A5 (https=
JP2024519814A5 (https=
Inventor
カズミエルスキ，ヴィエスワフ
エム ドゥボウチック，ジーン
エム コールドウェル，リース
アダム スピーゲル，デヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2024519814A publication Critical patent/JP2024519814A/ja
Publication of JPWO2022245759A5 publication Critical patent/JPWO2022245759A5/ja
Publication of JP2024519814A5 publication Critical patent/JP2024519814A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023571295A 2021-05-17 2022-05-17 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物 Pending JP2024519814A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189522P 2021-05-17 2021-05-17
US63/189,522 2021-05-17
PCT/US2022/029535 WO2022245759A2 (en) 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products

Publications (3)

Publication Number Publication Date
JP2024519814A true JP2024519814A (ja) 2024-05-21
JPWO2022245759A5 JPWO2022245759A5 (https=) 2025-05-23
JP2024519814A5 JP2024519814A5 (https=) 2025-05-23

Family

ID=84140970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571295A Pending JP2024519814A (ja) 2021-05-17 2022-05-17 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物

Country Status (11)

Country Link
US (1) US20240252674A1 (https=)
EP (1) EP4340891A4 (https=)
JP (1) JP2024519814A (https=)
KR (1) KR20240012380A (https=)
CN (1) CN117750979A (https=)
AU (1) AU2022275832A1 (https=)
CA (1) CA3219517A1 (https=)
IL (1) IL307799A (https=)
MX (1) MX2023013272A (https=)
PH (1) PH12023553154A1 (https=)
WO (1) WO2022245759A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219475A1 (en) * 2021-05-17 2022-11-24 Wieslaw Kazmierski Compositions including conjugated therapy enhancers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514961A (ja) * 2003-01-13 2006-05-18 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 改善されたガストリン関連ペプチド化合物
JP2015512953A (ja) * 2012-04-16 2015-04-30 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
JP2017507905A (ja) * 2013-12-23 2017-03-23 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
US20180243284A1 (en) * 2015-09-10 2018-08-30 University Of Yamanashi Therapeutic agent or treatment method for philadelphia chromosome-positive (ph+) acute lymphocytic leukemia (all) having ikzf1 mutation
JP2020528937A (ja) * 2017-07-26 2020-10-01 クレオ ファーマシューティカルズ， インコーポレイテッド 普遍的なａｂｔ化合物及びその使用
JP2020534296A (ja) * 2017-09-18 2020-11-26 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3617235B1 (en) * 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
AU2020299157A1 (en) * 2019-07-03 2022-01-20 Kleo Pharmaceuticals, Inc. CD38-binding agents and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514961A (ja) * 2003-01-13 2006-05-18 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 改善されたガストリン関連ペプチド化合物
JP2015512953A (ja) * 2012-04-16 2015-04-30 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
JP2017507905A (ja) * 2013-12-23 2017-03-23 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
US20180243284A1 (en) * 2015-09-10 2018-08-30 University Of Yamanashi Therapeutic agent or treatment method for philadelphia chromosome-positive (ph+) acute lymphocytic leukemia (all) having ikzf1 mutation
JP2020528937A (ja) * 2017-07-26 2020-10-01 クレオ ファーマシューティカルズ， インコーポレイテッド 普遍的なａｂｔ化合物及びその使用
JP2020534296A (ja) * 2017-09-18 2020-11-26 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法

Also Published As

Publication number Publication date
WO2022245759A3 (en) 2023-02-02
MX2023013272A (es) 2023-11-30
KR20240012380A (ko) 2024-01-29
AU2022275832A1 (en) 2023-12-14
US20240252674A1 (en) 2024-08-01
CN117750979A (zh) 2024-03-22
WO2022245759A2 (en) 2022-11-24
CA3219517A1 (en) 2022-11-24
IL307799A (en) 2023-12-01
PH12023553154A1 (en) 2024-03-11
EP4340891A4 (en) 2025-07-02
EP4340891A2 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
JP7221259B2 (ja) 改変した抗体組成物、それを作製および使用する方法
JP5913307B2 (ja) 多機能性抗体複合体
US20100189727A1 (en) Masking Ligands For Reversible Inhibition Of Multivalent Compounds
JP2020523413A (ja) 操作された抗体化合物およびこれらの抱合体
CN110998329A (zh) 定性和/或定量分析可活化抗体的特性的方法及其用途
CN103748222B (zh) 新型抗人ngf抗体
AU2021217353A1 (en) IL-7Rαγc binding compounds
AU2020378282A1 (en) Dual IL-2R and IL-7R binding compounds
JP2022518743A (ja) 抗体－薬物コンジュゲート用のグリコシド含有ペプチドリンカー
JP2020531430A (ja) 抗体を標的とする抗ｃｔｌａ４プロボディ療法
JP2024519814A (ja) 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物
JP6583411B2 (ja) 薬物複合体
US20240156974A1 (en) Compositions and methods for modulation of antibody activity
JP2024519031A (ja) コンジュゲート療法エンハンサーを含む組成物
CN118255900A (zh) 具有抗体募集功能的fgfr1拮抗肽衍生物及其合成和抗肿瘤应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317